Conference Reports for NATAP

HIV Glasgow 23-26 October 2016 Glasgow, UK Back

Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48 week results from the randomized, controlled, phase 3, non-inferiority TALENT study       Reported by Jules Levin HIV Glasgow Oct 23-26 2016   Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients [AIDS Research and Therapy2016].....https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-016-0091-1   ICAAC/2012: New gp41 Fusion Inhibitor Has Long Half-Life, Anti-HIV Activity in HIV+ Naïve  http://www.natap.org/2012/ICAAC/ICAAC_27.htm   Press announcement June 2016   http://www.prnewswire.com/news-releases/frontier-biotechs-long-acting-hiv-1-fusion-inhibitor-albuvirtide-meets-48-week-primary-objective-interim-results-of-a-phase-3-trial-300279903.html